DBV Technologies Announces the Results of its 2026 Combined General Meeting
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) held its 2026 Combined General Meeting in Châtillon, France, on June 3, 2026. The meeting was chaired by Michel de Rosen, Chairman of the Board of Directors.
Shareholders approved all resolutions submitted by the Board. Detailed resolutions and voting results are available on the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – DBVT
In the Jun 4 session, DBVT declined 0.68%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | AGM announcement | Neutral | +1.2% | Outlined June 3, 2026 Combined General Meeting logistics and materials access. |
| May 12 | Conference participation | Neutral | -2.0% | Disclosed CEO fireside chat at H.C. Wainwright BioConnect investor conference. |
| Apr 30 | Quarterly earnings | Negative | -5.4% | Reported Q1 2026 loss and spending increases alongside cash position update. |
| Apr 02 | Share count update | Neutral | -3.3% | Published total shares and voting rights as of March 31, 2026. |
| Mar 26 | Annual filings | Neutral | -1.0% | Filed 2025 Form 10-K and 2025 Universal Registration Document with regulators. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent corporate and regulatory updates have more often coincided with modest negative price reactions, with only occasional small gains around routine announcements.
Over the past months, DBV Technologies has focused on governance, disclosure, and financial updates. It announced its 2026 Combined General Meeting details, conference participation, and filed its 2025 Form 10-K and Universal Registration Document. Q1 2026 results highlighted cash of $229M and a net loss of $47.6M. A March update detailed 296,042,447 shares and nearly matching voting rights. Today’s AGM voting results follow directly from the previously announced meeting agenda and proxy process.
Key Terms
isin financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Châtillon, France, June 3, 2026
DBV Technologies Announces the Results of its 2026 Combined General Meeting
Shareholders approved all proposed resolutions
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Board of Directors (the “Board”).
The Company’s shareholders approved all resolutions submitted by the Board.
The resolutions and voting results are posted on the Company’s website: 2026 Annual General Meeting | DBV Technologies
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of the VIASKIN Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
